Directorio

People in the study will be split into two groups. One group will take a medicine called IDRX-42 every day as a white tablet. The other group will take a medicine called sunitinib in a capsule for 4 weeks, then stop for 2 weeks, and keep repeating that schedule. Both medicines are taken by mouth with a glass of water. Before starting, each person will have tests to make sure it is safe for them to join the study.

This study has five parts: screening, treatment, end of treatment, safety check, and long-term follow-up. - Part A: People will try different amounts of a new medicine called KTX-2001 to find the safest dose. - Part B: People will take the best dose of KTX-2001 along with another medicine called darolutamide. KTX-2001 is taken on an empty stomach. Darolutamide is taken with food twice a day. You will get medicine to take at home and write down when you take it in a diary. You will have regular check-ups, scans, heart tests, and maybe a biopsy. After treatment, doctors will check on you for safety and follow up every few months until your cancer gets worse or you start a new treatment.

We are doing this study to learn more about how environmental contaminants (e.g., "forever chemicals") can affect people's likelihood of developing liver disease.

This study doesn't give any treatment. Instead, doctors will collect samples like blood, pee, spit, and a nose swab two times while you're in the hospital. Later, someone from the study will call you after 60 days to ask how you're feeling.

We are doing this study to see if the study drug, PT886, with or without chemotherapy and/or pembrolizumab, is a safe and effective option for gastric and pancreatic cancer. We are also trying to find the best dose of the study drug to use.

We are doing this study to see if the study drug, QTX3034, either with or without cetuximab, is safe and effective for treating KRAS G12D mutated cancer. We are also trying to find the best dose of QTX3034 to use.

We are doing this study to find out if an investigational drug called QTX3544 (the study drug) is a safe and effective option for KRAS G12V mutated cancer. We want to know how well it works on its own and in combination with a drug called cetuximab, and we are also trying to find the best dose of the study drug to use.

We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.